MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
L39373
MolDX provides limited coverage for molecular DNA/RNA assays to aid diagnosis of cutaneous melanoma only when ALL conditions are met: ordered by a board-certified/board-eligible dermatopathologist; the specimen is a primary, non-metastatic, non-re-excision cutaneous melanocytic lesion with an equivocal diagnosis after standard-of-care and ancillary tests; the specimen contains a representative suspicious area; and the assay is validated, demonstrates AV/CV/CU and has undergone MolDX technical assessment. Tests previously performed on the same lesion, assays on metastatic or re-excision specimens, tests lacking validation or MolDX TA, or orders from non-dermatopathologists are not covered; one assay per clinical lesion is permitted.
"Test is ordered by a board-certified or board-eligible dermatopathologist."
Sign up to see full coverage criteria, indications, and limitations.